|Dr. Anil R. Diwan Ph.D.||Chairman, Pres and Sec.||420.83k||N/A||58|
|Dr. Eugene Seymour M.D., MPH||Chief Exec. Officer and Director||420.83k||N/A||76|
|Ms. Meeta R. Vyas SB, MBA||Chief Financial Officer||129.6k||N/A||58|
|Dr. Randall W. Barton Ph.D.||Chief Scientific Officer and Chief Regulatory Officer||N/A||N/A||70|
|Dr. Jayant Tatake Ph.D.||VP of R&D||N/A||N/A||N/A|
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; anti-viral eye drops against external eye viral infections; and other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
NanoViricides, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.